AIM:To evaluate the safety and effectiveness of our new cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemoperfusion(HIPEC)program.METHODS:Retrospective review of patients with gastrointestinal malignanci...AIM:To evaluate the safety and effectiveness of our new cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemoperfusion(HIPEC)program.METHODS:Retrospective review of patients with gastrointestinal malignancies who were suitable candidates for CRS and HIPEC between 12/1/2009 and 10/1/2010.All clinicopathologic data were reviewed with a special focus on the surgical outcome and the postoperative morbidity and mortality.RESULTS:Fourteen patients were identified.Median age was 64 years;seven were female.The primary tumors were:colonic(29%),appendiceal(36%),peritoneal mesothelioma(14%),gastric(7%),adenocarcinoma of unknown primary(7%),and gastrointestinal stromal tumor(7%).Eleven patients(79%)received CRS/HIPEC,three for palliation.Three patients that did not undergo CRS/HIPEC had an average peritoneal cancer index(PCI)of 25.The eight patients that underwent curative CRS/HIPEC had an average PCI of 10 and a completeness of cytoreduction score of 0(87.5%) or 1(12.5%).Postoperative morbidity was 36%;the worst adverse event was Grade 3 ileus.Mortality rate was 0%.CONCLUSION:CRS with HIPEC is safe and feasible at tertiary institutions with fledgling programs.PCI is an accurate predictor of surgical outcomes.展开更多
文摘AIM:To evaluate the safety and effectiveness of our new cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemoperfusion(HIPEC)program.METHODS:Retrospective review of patients with gastrointestinal malignancies who were suitable candidates for CRS and HIPEC between 12/1/2009 and 10/1/2010.All clinicopathologic data were reviewed with a special focus on the surgical outcome and the postoperative morbidity and mortality.RESULTS:Fourteen patients were identified.Median age was 64 years;seven were female.The primary tumors were:colonic(29%),appendiceal(36%),peritoneal mesothelioma(14%),gastric(7%),adenocarcinoma of unknown primary(7%),and gastrointestinal stromal tumor(7%).Eleven patients(79%)received CRS/HIPEC,three for palliation.Three patients that did not undergo CRS/HIPEC had an average peritoneal cancer index(PCI)of 25.The eight patients that underwent curative CRS/HIPEC had an average PCI of 10 and a completeness of cytoreduction score of 0(87.5%) or 1(12.5%).Postoperative morbidity was 36%;the worst adverse event was Grade 3 ileus.Mortality rate was 0%.CONCLUSION:CRS with HIPEC is safe and feasible at tertiary institutions with fledgling programs.PCI is an accurate predictor of surgical outcomes.
